$0.51
5.98% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US85209E1091
Symbol
SPRB
Sector
Industry

Spruce Biosciences Inc Stock price

$0.51
-0.06 9.76% 1M
-0.19 26.57% 6M
-2.42 82.52% YTD
-0.89 63.41% 1Y
-2.29 81.71% 3Y
-14.49 96.59% 5Y
-14.49 96.59% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.03 5.98%
ISIN
US85209E1091
Symbol
SPRB
Sector
Industry

Key metrics

Market capitalization $21.16m
Enterprise Value $-35.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.77
EV/Sales (TTM) EV/Sales -5.02
P/S ratio (TTM) P/S ratio 2.98
P/B ratio (TTM) P/B ratio 0.41
Revenue growth (TTM) Revenue growth -1.40%
Revenue (TTM) Revenue $7.10m
EBIT (operating result TTM) EBIT $-43.24m
Free Cash Flow (TTM) Free Cash Flow $-46.50m
Cash position $60.06m
EPS (TTM) EPS $-0.96
P/E forward negative
P/S forward 3.65
EV/Sales forward negative
Short interest 0.59%
Show more

Is Spruce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Spruce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Spruce Biosciences Inc forecast:

1x Buy
25%
3x Hold
75%

Analyst Opinions

4 Analysts have issued a Spruce Biosciences Inc forecast:

Buy
25%
Hold
75%

Financial data from Spruce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.10 7.10
1% 1%
100%
- Direct Costs 0.05 0.05
83% 83%
1%
7.05 7.05
2% 2%
99%
- Selling and Administrative Expenses 14 14
15% 15%
200%
- Research and Development Expense 36 36
24% 24%
508%
-43 -43
18% 18%
-608%
- Depreciation and Amortization 0.05 0.05
83% 83%
1%
EBIT (Operating Income) EBIT -43 -43
18% 18%
-609%
Net Profit -39 -39
20% 20%
-555%

In millions USD.

Don't miss a Thing! We will send you all news about Spruce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Spruce Biosciences Inc Stock News

Neutral
Business Wire
15 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates. “We remain on track to ...
Neutral
Business Wire
29 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Inn...
Neutral
Accesswire
4 months ago
LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to ...
More Spruce Biosciences Inc News

Company Profile

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.

Head office United States
CEO Javier Szwarcberg
Employees 29
Founded 2014
Website www.sprucebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today